South Korea Daily Briefing

Korea Economic Daily reported Savills Investment Management's view that fading prospects of rate cuts are squeezing property owners and borrowers, but simultaneously creating an opening for private real estate debt specialists. The same rate environment driving today's KOSPI selloff (risk-off + financial sector pressure) is creating distressed-debt entry points in Korean commercial real estate. For investors looking beyond the equity drawdown, private credit at current Korean base rates offers inflation-adjusted yields unavailable during the low-rate era.

Chosun Ilbo's economic desk reported Tuesday that existing public redevelopment projects have recorded zero groundbreakings for five consecutive years, even as the government pledges to accelerate delivery. The Changsin 9-10 zone in Jongno-gu hit another delay as the district office postponed the project operator designation notice. For Korean construction and realty names already under pressure from higher financing costs, the regulatory overhang adds a structural headwind beyond today's market selloff.

Chosun Ilbo's science/economy desk reported Eli Lilly's Zepbound posted a 46% revenue surge as it dominates the obesity drug market. The Korea angle: Samsung Bioepis and Hanmi Pharmaceutical are developing GLP-1 biosimilar and next-gen obesity candidates — any evidence of durable obesity drug market growth at this scale raises the earnings trajectory for Korea's CRO and biologic CDMO names, even as the KOSPI's broad selloff today swept them lower alongside semis.